Loading...

BCRX BIOCRYST PHARMACEUTICALS INC Management Changes 8-K Filing

BCRY

BCRX

BIOCRYST PHARMACEUTICALS INC

(BCRX)

2025 8-K

Show Summary

Summary

Financial Statements

Stock Purchase Agreement

Clinical Trials

New Product Launches

Financial Statements

Management Changes

CFO Resignation

Financial Results

Investor Conference

Q3 Financial Results

Trial Enrollment

Financial Results and Busin...

Annual Meeting Approval

Financial Results Announcement

Financial Results Announcement

By-Laws Amendment

Financial Results

Departure of Directors

Commercialization Agreement...

Regulation FD Disclosure

License Agreement for Avora...

Financial Results Announcement

Clinical Trial Enrollment

Financial Results and Busin...

Annual Meeting Approval of ...

Financial Results and Busin...

External Links:

On July 25, 2025, Jon Stonehouse announced his retirement as CEO of BioCryst Pharmaceuticals effective December 31, 2025, with Charlie Gayer appointed as successor starting January 1, 2026, along with significant salary adjustments. The Board also expanded its size by one member, electing Gayer as a director effective the same day as his CEO position.

AI Assistant

BIOCRYST PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.